Publications

Beltran H, Yelensky R, Frampton GM, Park K, , MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al..  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. Eur Urol. 63(5):920-6.

Attard G, Beltran H.  2015.  Prioritizing precision medicine for prostate cancer.. Ann Oncol. 26(6):1041-2.

Choe H, Sboner A, Beltran H, Nanus D, Tagawa ST.  2016.  PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.. Thromb Res. 140 Suppl 1:S192.

Beltran H.  2014.  The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.. Mol Cancer Res. 12(6):815-22.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 4(30):563-577.

Beltran H, Rubin MA.  2013.  New strategies in prostate cancer: translating genomics into the clinic.. Clin Cancer Res. 19(3):517-23.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2016.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol.

Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM et al..  2016.  The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.. Clin Cancer Res. 6(22)

Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O.  2013.  Epigenomic alterations in localized and advanced prostate cancer.. Neoplasia. 15(4):373-83.

Beltran H, Antonarakis ES, Morris MJ, Attard G.  2016.  Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.. Am Soc Clin Oncol Educ Book. (35):131-41.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopolou E, Chakravarthi BV, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 3(22):298-305.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R et al..  2013.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.. Neoplasia . (1):1-10.

Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):386-9.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H et al..  2014.  Aggressive variants of castration-resistant prostate cancer.. Clin Cancer Res. 20(11):2846-50.